loader
Please Wait
Applying Filters...

EuroAPI Header EuroAPI Header

X

Technical details about Prazepam, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
2D Structure
1. Also known as: Demetrin, Lysanxia, Centrax, Trepidan, Verstran, 2955-38-6
Molecular Formula
C19H17ClN2O
Molecular Weight
324.8  g/mol
InChI Key
MWQCHHACWWAQLJ-UHFFFAOYSA-N
FDA UNII
Q30VCC064M

A benzodiazepine that is used in the treatment of ANXIETY DISORDERS.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
7-chloro-1-(cyclopropylmethyl)-5-phenyl-3H-1,4-benzodiazepin-2-one
2.1.2 InChI
InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
2.1.3 InChI Key
MWQCHHACWWAQLJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CC1CN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4
2.2 Other Identifiers
2.2.1 UNII
Q30VCC064M
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Centrax

2. Demetrin

3. Lysanxia

4. Mono Demetrin

5. Reapam

2.3.2 Depositor-Supplied Synonyms

1. Demetrin

2. Lysanxia

3. Centrax

4. Trepidan

5. Verstran

6. 2955-38-6

7. Prazepamum [inn-latin]

8. W 4020

9. K-373

10. Prazepam Civ

11. 2h-1,4-benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-

12. Nsc 277179

13. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-3h-1,4-benzodiazepin-2-one

14. 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2h-1,4-benzodiazepin-2-one

15. W-4020

16. Nsc-277179

17. 7-chloro-1-cyclopropylmethyl-5-phenyl-1h-1,4-benzodiazepin-2(3h)-one

18. Chebi:8362

19. Q30vcc064m

20. Prazene

21. Sedapran

22. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one

23. Ncgc00168256-01

24. Prazeene

25. Prazepamum

26. Settima

27. Dsstox_cid_1181

28. 2h-1,4-benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(cyclopropylmethyl)-5-phenyl-

29. Dsstox_rid_75994

30. Dsstox_gsid_21181

31. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one

32. Centrax (tn)

33. Cas-2955-38-6

34. Einecs 220-975-8

35. Brn 0895797

36. Unii-q30vcc064m

37. Dea No. 2764

38. Prazepam [usan:usp:inn:ban:jan]

39. Prazepam [iarc]

40. Prazepam [usan]

41. Prazepam [inn]

42. Prazepam [jan]

43. Prazepam [mi]

44. Prazepam [vandf]

45. Prazepam [mart.]

46. Chembl969

47. Prazepam [who-dd]

48. Schembl78272

49. Mls003899231

50. Prazepam [orange Book]

51. Prazepam Civ [usp-rs]

52. Gtpl7275

53. Prazepam (jp17/usan/inn)

54. Zinc1971

55. Prazepam [ep Monograph]

56. Dtxsid4021181

57. Prazepam 0.1 Mg/ml In Methanol

58. Prazepam 1.0 Mg/ml In Methanol

59. Tox21_112615

60. Tox21_200076

61. Nsc277179

62. Prazepam 1000 Microg/ml In Methanol

63. Db01588

64. Ncgc00168256-02

65. Ncgc00257630-01

66. Smr000058725

67. Db-047601

68. C07366

69. D00470

70. Wln: T67 Gnv Jn Ihj Cg Kr& G1- Al3tj

71. Q2149443

72. 7-chloro-1-(cyclopropylmethyl)-1,4-benzodiazepin-2-one

73. Prazepam, European Pharmacopoeia (ep) Reference Standard

74. 2h-1, 1,3-dihydro-7-chloro-1-(cyclopropylmethyl)-5-phenyl-

75. 2h-1, 7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-

76. Prazepam, United States Pharmacopeia (usp) Reference Standard

77. 7-chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one #

78. Prazepam Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 324.8 g/mol
Molecular Formula C19H17ClN2O
XLogP33.6
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count2
Rotatable Bond Count3
Exact Mass324.1029409 g/mol
Monoisotopic Mass324.1029409 g/mol
Topological Polar Surface Area32.7 Ų
Heavy Atom Count23
Formal Charge0
Complexity482
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

For the treatment of anxiety disorders.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Prazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.


5.2 MeSH Pharmacological Classification

Anti-Anxiety Agents

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)


GABA Modulators

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)


5.3 ATC Code

N05BA11

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


N - Nervous system

N05 - Psycholeptics

N05B - Anxiolytics

N05BA - Benzodiazepine derivatives

N05BA11 - Prazepam


5.4 Metabolism/Metabolites

Hepatic.


5.5 Biological Half-Life

36-200 hours


5.6 Mechanism of Action

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.


Post Enquiry
POST ENQUIRY